<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726440</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A01022-51</org_study_id>
    <nct_id>NCT00726440</nct_id>
  </id_info>
  <brief_title>Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients?</brief_title>
  <official_title>Are the Continous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients With Poor Metabolic Control?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;Capteur Evadiac&quot; study group, composed of French and Belgian diabetologists, has
      designed a 1 year randomized controlled multicenter study in order to define what should be
      the best clinical way of using continuous glucose monitoring in the long term to improve
      metabolic control in uncontrolled type 1 diabetes patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to determine whether patients with chronically poor
      glycaemic control as evidenced by HbA1c &gt;= 8% twice can achieve improved metabolic control
      using during one year CGM together with educative program about insulin adaptation doses
      compared to conventional self monitoring finger sticks with educative program about insulin
      adaptation doses alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of HbA1c mean between the 3 groups</measure>
    <time_frame>at 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of glucose stability in the 3 groups</measure>
    <time_frame>inclusion, M3, M6, M9, M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe hypoglycaemic episodes and ketoacidosis episodes during the study period</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of symptomatic benign hypoglycaemic episodes during the week prior to each visit. inclusion and prior to M3, M6, M9, M12</measure>
    <time_frame>prior to inclusion and prior to M3, M6, M9, M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of HbA1c in patients treated by pump to those treated by multiple daily injection</measure>
    <time_frame>inclusion, M3, M6, M9, M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Quality of Life (DQOL and SF36) and patient's satisfaction in the 3 groups</measure>
    <time_frame>inclusion and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of weight, insulin doses, in each group</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of the sensors consumption in group 1 and 2 and the evolution in time of this consumption</measure>
    <time_frame>study period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group1-patient</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2-diabetologist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:
HbA1c&gt;=7.5%
1 severe hypoglycaemia or more
More than 4 benign hypoglycaemia per week
According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:
step 1: 3 sensors per month
step 2: 4 sensors per month
step 3: 5 sensors per month
step 4: continuous use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3-Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usual follow up with self-monitoring blood glucose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Navigator®</intervention_name>
    <description>Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data</description>
    <arm_group_label>Group1-patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Navigator®</intervention_name>
    <description>Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.</description>
    <arm_group_label>Group2-diabetologist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will have their usual follow up with self-monitoring blood glucose</description>
    <arm_group_label>Group3-Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes for ≥ 12 months or more (including Cpeptide negative secondary
             diabetes)

          -  Children between 8 and 18 years old

          -  Adults between 18 and 60 years old

          -  Patients treated with basal-bolus insulin regimens, pump or multiple daily injection,
             only with analogs, for at least 6 months

          -  Performing at least 2 finger sticks glucose controls per day

          -  Able and motivated to use the device

          -  HbA1c ≥ 8% twice with HPLC method(DCA 2000 excluded)

          -  Written informed consent obtained prior to enrollment in the study

        Exclusion Criteria:

          -  Blindness or impaired vision so the screen cannot be recognized

          -  Allergy to sensor

          -  Active proliferative retinopathy not stabilized by laser or vitrectomy occurence in
             the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy
             that may require photocoagulation or surgical treatment during study

          -  Treatment with systemic corticosteroid or medication known to influence insulin
             sensitivity in the 3 months prioir to visit 1

          -  Pregnancy

          -  Manifest psychiatric disturbance

          -  Presence of any conditions (medical, including clinically significant abnormal
             laboratory test, psychological, social or geographical) actuel or anticipated that the
             investigators feels would compromise the patient safety or limit his/her successful
             participation in the study.

          -  Hemoglobinopathy that interfers with HbA1c measurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Riveline, MD</last_name>
    <role>Study Director</role>
    <affiliation>CH Sud Francilien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart Tilman Liège</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH SUD Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Marseille Hôpitaux Sud</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Jeanne d'Arc</name>
      <address>
        <city>Nancy</city>
        <zip>54201</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims-Hôpital Américain</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims-Hôpital Robert debré</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bellevue</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Real Time Continuous Glucose Monitoring System</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Navigator®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

